The company's stock declined after the FDA delayed its decision on the new oral weight-loss pill, Orforglipron, pushing the review date to April. This postponement creates uncertainty and delays potential revenue. However, the company is highlighted as a top long-term growth stock by analysts, with strong expected Q4 results driven by demand for its existing weight-loss drugs. It continues to advance a robust pipeline with multiple early-stage programs and novel therapies in development.